Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials

Journal of Clinical Oncology

Volumn 17, Issue 8, 1999, Pages 2572-2578

  Wong, Eric T ^a   Hess, Kenneth R ^a   Gleason, Mary Jo ^a   Jaeckle, Kurt A ^a   Kyritsis, Athanassios P ^a   Prados, Michael D ^a   Levin, Victor A ^a   Alfred Yung, W K ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BETA INTERFERON; CARBOPLATIN; FLUOROURACIL; MENOGARIL; PROCARBAZINE; RETINOIC ACID;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; GLIOBLASTOMA; GLIOMA CELL; HISTOPATHOLOGY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; META ANALYSIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME;

EID: 0032767387     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.8.2572     Document Type: Article

References (24)

1. Burger PC, Vogel FS, Green SB, et al: Glioblastoma multiforme and anaplastic astrocytoma, pathologic criteria and prognostic implications. Cancer 56:1106-1111, 1985
2. Rosenblum ML, Gerosa M, Dougherty DV, et al: Age-related chemosensitivity of stem cells from human malignant brain tumors. Lancet 1:885-887, 1982
3. Grant R, Liang BC, Page MA, et al: Age influences chemotherapy response in astrocytomas. Neurology 45:929-933, 1995
4. Nelson JS, Tsukada Y, Schoenfeld D, et al: Necrosis as a prognostic criterion in malignant supratentorial, astrocytic gliomas. Cancer 52:550-554, 1983
5. SC Schold, Jr, Burger PC, Mendelsohn DB, et al: Primary Tumors of the Brain and Spinal Cord. Boston, MA, Butterworth-Heinemann, 1997, pp 51-54
6. Wood JR, Green SB, Shapiro WR, et al: The prognostic importance tumor size in malignant gliomas: A computed tomographic scan study by the Brain Tumor Cooperative Group. J Clin Oncol 6:338-343, 1988
7. Walker MD Green SB, Byar DP, et al: Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 303:1323-1329, 1989
8. Gehan EA: The determination of the number of patients required in a preliminary and follow-up trial of a new chemotherapeutic agent. J Chronic Dis 13:346-353, 1961
9. Eagan RT Scott M: Evaluation of prognostic factors in chemotherapy of recurrent brain tumors. J Clin Oncol 1:38-44, 1983
10. Rostomily RC, Spence AM, Duong D, et al: Multimodality management of recurrent adult malignant gliomas: Results of a phase II multiagent chemotherapy study and analysis of cytoreductive surgery. Neurosurgery 35:378-388, 1994
11. Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10, 1989
12. Levin VA, Wilson CB, Craft D, et al: Criteria for evaluating malignant brain tumor patients undergoing chemotherapy. J Neurosurg 47:329-335, 1977
13. Collett D: Modelling of Binary Data. New York, NY, Chapman and Hall, 1992
14. Cox DR, Oakes D: Analysis of Survival Data. New York, NY, Chapman and Hall, 1984
15. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:475-481, 1958
16. Clark LA, Pregibon D: Tree-based models, in Chambers JM, Hastie JJ (eds): Statistical Models in S. Belmont, CA, Wadsworth, 1992, pp 377-419
17. Therneau T, Grambsch P, Fleming T: Martingale based residuals for survival models. Biometrika 77:147-160, 1990
18. Salcman M: Resection and reoperation in neuro-oncology: Rationale and approach. Neurol Clin 3:831-842, 1985
19. Levin VA, Prados MD: Treatment of recurrent gliomas and metastatic brain tumors with a polydrug protocol designed to combat nitrosourea resistance. J Clin Oncol 10:766-771, 1992
20. Fine HA, Dear KBG, Loeffler JS, et al: Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 71:2585-2597, 1993
21. MacDonald DR, Cascino TL, Schold SC, et al: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277-1280, 1990
22. Yung WKA, Steck PA, Kelleher PJ, et al: Growth inhibitory effect of recombinant alpha and beta interferon on human glioma cells. J Neurooncol 5:323-330, 1987
23. Taki T, Ohnishi T, Arita N, et al: Anti-proliferative effects of TNP-470 on human malignant glioma in vivo: Potent inhibition of tumor angiogenesis. J Neurooncol 19:251-258, 1994
24. Bajan B, Ross G, Lim CC, et al: Survival in patients with recurrent glioma as a measure of treatment efficacy: Prognostic factors following nitrosourea chemotherapy. Eur J Cancer 12:1809-1815, 1994